PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The recognition of a correlation between patatin-like phospholipase domain containing-protein 3 (PNPLA3) rs738409 (C>G) and the severity of liver steatosis or fibrosis in chronic hepatitis C (CHC) has not reached a consensus. This meta-analysis sought to investigate with accuracy the association between the PNPLA3 rs738409 (C>G) polymorphism and liver steatosis and advanced fibrosis in CHC patients. Methods: We performed a comprehensive literature search from the PubMed, Embase, Web of Science, and Google Scholar databases up to December 31, 2014. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Statistical analyses were performed using Stata 12.0 software. Results: The meta-analysis revealed the severity of liver fibrosis was significantly higher in CHC patients with PNPLA3 rs738409 GG in Caucasians (versus CC+CG: OR, 2.29; 95% CI, 1.57 to 3.35; p<0.05) but not Asian populations. In Caucasians, liver steatosis was also more severe in CHC patients with rs738409 GG (versus CC+CG; OR, 4.33; 95% CI, 2.59 to 7.22; p<0.05). The sensitivity analysis indicated the results of this meta-analysis were stable and no publication bias was detected. Conclusions: PNPLA3 rs738409 (C>G) was associated with the risk of both advanced liver fibrosis and steatosis in patients with CHC, especially among Caucasian populations.
Abstract
Background/Aims: The recognition of a correlation between patatin-like phospholipase domain containing-protein 3 (PNPLA3) rs738409 (C>G) and the severity of liver steatosis or fibrosis in chronic hepatitis C (CHC) has not reached a consensus. This meta-analysis sought to investigate with accuracy the association between the PNPLA3 rs738409 (C>G) polymorphism and liver steatosis and advanced fibrosis in CHC patients. Methods: We performed a comprehensive literature search from the PubMed, Embase, Web of Science, and Google Scholar databases up to December 31, 2014. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Statistical analyses were performed using Stata 12.0 software. Results: The meta-analysis revealed the severity of liver fibrosis was significantly higher in CHC patients with PNPLA3 rs738409 GG in Caucasians (versus CC+CG: OR, 2.29; 95% CI, 1.57 to 3.35; p<0.05) but not Asian populations. In Caucasians, liver steatosis was also more severe in CHC patients with rs738409 GG (versus CC+CG; OR, 4.33; 95% CI, 2.59 to 7.22; p<0.05). The sensitivity analysis indicated the results of this meta-analysis were stable and no publication bias was detected. Conclusions: PNPLA3 rs738409 (C>G) was associated with the risk of both advanced liver fibrosis and steatosis in patients with CHC, especially among Caucasian populations.
참고문헌 (34)
- Shepard CW, "Global epidemiology of hepatitis C virus infection", Lancet Infect Dis, 5, pp.558~567 (2005)
- Seeff LB, "The history of the"natural history"of hepatitis C(1968-2009)", Liver Int, 29(1), pp.89~99 (2009)
- Niederau C, "Prognosis of chronic hepatitis C: results of a large, prospective cohort study", Hepatology, 28, pp.1687~1695 (1998)
- Bochud PY, "Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C", J Hepatol, 51, pp.655~666 (2009)
- Davis GL, "Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression", Gastroenterology, 138(e6), pp.513~521 (2010)
- Leandro G, "Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data", Gastroenterology, 130, pp.1636~1642 (2006)
- Missiha SB, "Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors", Gastroenterology, 134, pp.1699~1714 (2008)
- Poynard T, "Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups", Lancet, 349, pp.825~832 (1997)
- Wright M, "Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection:a cross sectional and longitudinal study", Gut, 52, pp.574~579 (2003)
- Stattermayer AF, "Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C", J Hepatol, 57, pp.492~498 (2012)
- Valenti L, "Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin", Aliment Pharmacol Ther, 35, pp.1434~1442 (2012)
- Stattermayer AF, "Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C", Liver Int, 34, pp.388~395 (2014)
- Miyashita M, "Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C", J Viral Hepat, 19, pp.608~614 (2012)
- Trepo E, "Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C", Hepatology, 54, pp.60~69 (2011)
- Stang A, "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses", Eur J Epidemiol, 25, pp.603~605 (2010)
- Valenti L, "The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver", J Hepatol, 55, pp.1409~1414 (2011)
- Jackson D, "Quantifying the impact of between-study heterogeneity in multivariate meta-analyses", Stat Med, 31, pp.3805~3820 (2012)
- Peters JL, "Comparison of two methods to detect publication bias in meta-analysis", JAMA, 295, pp.676~680 (2006)
- Zintzaras E, "HEGESMA: genome search meta-analysis and heterogeneity testing", Bioinformatics, 21, pp.3672~3673 (2005)
- Romeo S, "Genetic variation in PNPLA3confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
- Rotman Y, "The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease", Hepatology, 52, pp.894~903 (2010)
- Valenti L, "Homozygosity for the patatin-like phospholipase-3", adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease, 2010, pp.51, 1209~1217
- Stickel F, "Genetic variation in the PNPLA3gene is associated with alcoholic liver injury in Caucasians", Hepatology, 53, pp.86~95 (2011)
- Tian C, "Variant in PNPLA3 is associated with alcoholic liver disease", Nat Genet, 42, pp.21~23 (2010)
- Trepo E, "Common polymorphism in the PNPLA3", adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease, 2011, pp.55, 906~912
- Chung KC, "A practical guide to meta-analysis", J Hand Surg Am, 31, pp.1671~1678 (2006)
- Dennis J, "Bias in the case-only design applied to studies of gene-environment and gene-gene interaction:a systematic review and meta-analysis", Int J Epidemiol, 40, pp.1329~1341 (2011)
- Rosenthal R, "Meta-analysis: recent developments in quantitative methods for literature reviews", Annu Rev Psychol, 52, pp.59~82 (2001)
- Agundez JA, "Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease", PLoS One, 7, pp.e37998~ (2012)
- Valenti L, "Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients", J Hepatol, 56, pp.1209~1210 (2012)
- Balagopal A, "IL28B and the control of hepatitis C virus infection", Gastroenterology, 139, pp.1865~1876 (2010)
- Thomas DL, "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus", Nature, 461, pp.798~801 (2009)
- Smith DB, "Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource", Hepatology, 59, pp.318~327 (2014)
- Thakkinstian A, "A method for meta-analysis of molecular association studies", Stat Med, 24, pp.1291~1306 (2005)